Back to Search
Start Over
Immunogenicity and reactogenicity of high- vs. standard-dose trivalent inactivated influenza vaccine in healthcare workers: a pilot randomized controlled trial.
- Source :
-
Clinical Microbiology & Infection . Feb2019, Vol. 25 Issue 2, p217-224. 8p. - Publication Year :
- 2019
-
Abstract
- Abstract Objectives To compare immunogenicity, reactogenicity and acceptability of high- and standard-dose trivalent inactivated influenza vaccine (HDTIV, SDTIV) in 18- to 64-year-olds. Methods We randomized 18- to 64-year-olds to HDTIV or SDTIV in two consecutive years. We collected serum on days 0 and 21, measured haemagglutination inhibition geometric mean titres (GMT) and compared seroconversion, day 21 titres, seroprotection, reactogenicity and acceptability. Results Immunogenicity was evaluable in 42 of 47 2014 participants, all 33 both-year participants and 87 of 90 2015-only participants. First-dose HDTIV recipients experienced seroconversion more frequently than SDTIV recipients to A(H3N2) in 2014 (13/21, 62% vs. 4/21, 19%, p 0.01) and to all vaccine strains in 2015: (A(H1N1): 24/42, 57% vs. 15/59, 25%; A(H3N2): 42/42, 100% vs. 47/59, 80%; B: 25/42, 60% vs. 13/59, 22%; all p <0.01). Day 21 haemagglutination inhibition GMT were higher in first and two sequential-year HDTIV vs. SDTIV recipients: A(H1N1): GMT 749 and 768 vs. 384 (p <0.0001, p 0.002); A(H3N2): 1238 and 956 vs. 633 (p 0.0003, p 0.1); and B: 1113 and 1086 vs. 556 (p 0.0005, p 0.02). HDTIV was more reactogenic (local pain score 3 vs. 1 of 10 on day 0/1, p 0.0003), but recipients were equally willing to be revaccinated (HDTIV: 76/83 (92%); SDTIV: 76/80 (95%), p 0.54). The ratios of day 21 GMT in SDTIV recipients vaccinated in 0 to 4 prior years to those in SDTIV and HDTIV recipients vaccinated in 15 or more prior years were A(H1N1): 3.73 and 1.38; A(H3N2) 3.07 and 1.16; and B: 2.01 and 1.21. Conclusions HDTIV is more immunogenic and reactogenic and as acceptable as SDTIV in 18- to 64-year-olds. [ABSTRACT FROM AUTHOR]
- Subjects :
- *INFLUENZA vaccines
*SERUM
*SEROCONVERSION
*BLOOD agglutination
*VACCINES
Subjects
Details
- Language :
- English
- ISSN :
- 1198743X
- Volume :
- 25
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Clinical Microbiology & Infection
- Publication Type :
- Academic Journal
- Accession number :
- 134274843
- Full Text :
- https://doi.org/10.1016/j.cmi.2018.05.002